ClinicalTrials.gg
CompletedNCT06716216Updated Nov 13, 2026

A Study of BGM0504 in Participants With Type 2 Diabetes

A Phase 3 interventional study of Drug: 5 mg BGM0504 Administered SC and Drug:10 mg BGM0504 Administered SC in Type 2 Diabetes Mellitus (T2DM), sponsored by BrightGene Bio-Medical Technology Co., Ltd.. Completed at 1 site in China. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-11-13.

Sponsored by BrightGene Bio-Medical Technology Co., Ltd. · Phase 3, Interventional, and Treatment

Updated Nov 13, 2026Now CompletedNow Active, not recruiting+6 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
553
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 909 studies in Diabetes Mellitus, Type 2 with a site in China — 205 open to participants now, 228 under way, 46 of them phase 3. Diabetes Mellitus, Type 2 · China.

Enrollment
150th of 767
553 · median 199
Started
2025
with 79 others
Phase 3
207 of 909
38 open now
Registered
709th of 909
by date

Among the 909 studies in Diabetes Mellitus, Type 2 with a site in China, this one is the 150th largest by enrollment of the 767 interventional ones that give a count, is one of 80 that started in 2025, is one of 207 in phase 3, and was the 709th registered.

Diabetes Mellitus, Type 2

10,386 studies on the registry are indexed under Diabetes Mellitus, Type 2; 1,411 are open to participants now.

Browse Diabetes Mellitus, Type 2 studies →

Open to participants now

205 of the 909 studies in Diabetes Mellitus, Type 2 with a site in China are open now. Recruiting first, the newest first:

200 more — sign in →

All 205 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 880 Diabetes Mellitus, Type 2 studies recruiting now, 374 (43%) set no upper age limit and 380 (43%) stop at 75 or younger; 52 take children under 18; 204 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 909 studies in Diabetes Mellitus, Type 2 with a site in China, or all of them as a file.
02

Study summary

This trial is conducted in China. The aim of the trial is to evaluate the efficacy and safety of BGM0504 versus semaglutide as add-on to metformin and/or sulfonylureas in patients with type 2 diabetes

03

Conditions studied

  • Type 2 Diabetes Mellitus (T2DM)
04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • ■ Have been diagnosed with type 2 diabetes mellitus (T2DM);

    • Metformin is used in screening : 1) After used stable-dose metformin (≥1500 mg/day) or maximum tolerated (\< 1500mg but≥1000mg daily) for 8 weeks before screening; 2)Metformin treatment dose \<1500mg/day at Screening and have not reached the maximum tolerated dose ;3) Metformin combined with daily fixed-dose sulfonylureas (minimum therapeutic dose on the drug label) had been stable for ≥8 weeks when entering the induction period.
    • Have a ≥23 kilograms per meter squared (kg/m²) at screening;
    • Be of stable weight (± 5%) for at least 3 months before screening;
    • Have between ≥7.5% and ≤11.0%;

Exclusion criteria

Exclusion Criteria:

  • ■ Previous diagnosis of type 1 diabetes, special type diabetes;

    • There are malignant tumors within 5 years before screening, or patients are in latent of clinical malignant tumors (except patients with skin basal cell carcinoma and squamous cell carcinoma, cervical carcinoma in situ, prostate carcinoma in situ or papillary thyroid carcinoma who have no recurrence after surgery).
    • Have had chronic or acute pancreatitis any time prior to study entry;
    • Known allergic constitution (allergy to 3 or more kinds of food or drugs), or allergy to GLP-1 receptor agonists, or severe allergic diseases (asthma, urticaria, eczematous dermatitis, etc.) at screening;
    • Mentally incapacitated or speech-impaired;
    • Suspected or confirmed history of alcohol or drug abuse;
    • Pregnant or lactating woman;
    • The investigator considers that there are any other conditions that make it inappropriate to participate in this study.
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
553 participants (actual)

Study arms

  • Experimental
    Experimental: 5 mg BGM0504 5 milligrams (mg) BGM0504 administered subcutaneously (SC) once a week.

    Drug: BGM0504 Administered SC

    Drug: Drug: 5 mg BGM0504 Administered SC

  • Experimental
    Experimental: 10 mg BGM0504 10 mg BGM0504 administered SC once a week.

    Drug: BGM0504 Administered SC

    Drug: Drug:10 mg BGM0504 Administered SC

  • Active comparator
    Active Comparator: 1 mg Semaglutide 1 mg semaglutide administered SC once a week

    Drug: Semaglutide Administered SC

    Drug: Drug: Semaglutide Administered SC

Interventions

  • DrugDrug: 5 mg BGM0504 Administered SC

    Experimental: 5 mg BGM0504 5 milligrams (mg) BGM0504 administered subcutaneously (SC) once a week.

  • DrugDrug:10 mg BGM0504 Administered SC

    Experimental: 10 mg BGM0504 10 mg BGM0504 administered SC once a week.

  • DrugDrug: Semaglutide Administered SC

    Active Comparator: 1 mg Semaglutide 1 mg semaglutide administered SC once a week

This study also gives Semaglutide. No intervention listed here names it: that was found by reading the record.

06

What researchers measure

Primary outcomes

  1. Change From Baseline in Hemoglobin A1c (HbA1c)

    Change from baseline in HbA1c after 32 weeks of treatment.

    Time frame: Week 0 to Week 32

Secondary outcomes

  1. Change From Baseline in Body Weight

    Change from baseline in body weight after 52 weeks of treatment.

    Time frame: Week 0 to Week 52

  2. Change From Baseline in Hemoglobin A1c (HbA1c)

    Change from baseline in HbA1c after 52weeks of treatment.

    Time frame: Week 0 to Week 52

  3. Percentage of Participants With HbA1c Target Value of <7%

    Percentage of Participants With HbA1c Target Value of \<7% after 52weeks of treatment.

    Time frame: Week 0 to Week 52

  4. Percentage of Participants With HbA1c Target Value of <5.7%

    Percentage of Participants With HbA1c Target Value of \<5.7%after 52weeks of treatment.

    Time frame: Week 0 to Week 52

  5. Change From Baseline in Fasting Serum Glucose

    Change from baseline in FPG after 52 weeks of treatment.

    Time frame: Week 0 to Week 52

07

Study locations

1 site
08

Timeline

2 registry updates since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jan 2025 to primary completion in Aug 2026, 19 months.

Of 438 industry-sponsored phase 3 interventional studies under Diabetes Mellitus, Type 2, half reached primary completion within 19 months of starting (the median), counting those still running; a quarter within 14 and three quarters within 26. This study's 19 months is close to that.

Counting every sponsor, half of 525 studies reached it within 20 months; a quarter within 14 and three quarters within 30.

Start moved once since we started tracking on Sep 25, 2026: Nov 2024 → Jan 2025, on Oct 15, 2026.

Primary completion moved twice since we started tracking on Sep 25, 2026: Mar 2026 → Aug 2026, last on Nov 13, 2026.

Completion moved once since we started tracking on Sep 25, 2026: Nov 2026 → Aug 2026, on Nov 13, 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Nov 29, 2024
First posted
Dec 4, 2024
StartActual
Jan 13, 2025was Nov 2024
Primary completionActual
Aug 25, 2026was Mar 2026
CompletionActual
Aug 25, 2026was Nov 2026
Last update
Nov 13, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Recruiting→Active, not recruiting→Completed
changed Oct 15, 2026 · changed Nov 13, 2026
Sites
1 site added, 1 site removed
Show site
  • Peking University People's Hospital · Beijing, China
Show 1 removed
  • Peking University People's Hospital · Beijing, China
Oct 15, 2026
Start date
Nov 29, 2024→Jan 13, 2025
Oct 15, 2026
Primary completion
Mar 20, 2026→Aug 25, 2026 (actual)
moved 2 times, Oct 15, 2026 – Nov 13, 2026
Study completion
Nov 14, 2026→Aug 25, 2026 (actual)
Nov 13, 2026
Enrollment
537 (estimated)→553 (actual)
Nov 13, 2026
Show all 2 updates
  1. Nov 13, 2026
    Active, not recruiting→Completed
    Primary completion Nov 14, 2026→Aug 25, 2026 (now actual)
    Study completion Nov 14, 2026→Aug 25, 2026 (now actual)
    Enrollment 537 (estimated)→553 (actual)
  2. Oct 15, 2026
    Recruiting→Active, not recruiting
    1 site added, 1 site removed
    Show site
    • Peking University People's Hospital · Beijing, China
    Show 1 removed
    • Peking University People's Hospital · Beijing, China
    Start date Nov 29, 2024→Jan 13, 2025
    Primary completion Mar 20, 2026→Nov 14, 2026
    + 5 other changes: identifiers, verification date, oversight details, contact details and index terms

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

09

Registry details

Key details

Study ID
NCT06716216
Responsible party
Sponsor
First posted
Dec 4, 2024
Start date
Jan 13, 2025
Primary completion
Aug 25, 2026
Completion
Aug 25, 2026
Last update
Nov 13, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion